Pricing

TG Therapeutics Inc (TGTX)

followers ·
Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Michael S. Weiss
Employees:
290
2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY, 10014
(212) 554-4484
    Formally known as:
  • MANHATTAN PHARMACEUTICALS, INC.
  • MANHATTAN PHARMACEUTICALS, INC.
  • TG THERAPEUTICS, INC. NEW COMMON
Stock Split History
DateRatio
2011-07-14 1:50
2012-04-30 100:5625
TG Therapeutics, Inc. focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors. TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor.
All 13F Filers Prior Change Hedge Funds 1 Prior Change
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available